Innovation Pharmaceuticals Inc. is a clinical stage pharmaceutical company developing innovative therapies with anti-infective, oncology, anti-inflammatory and dermatology applications. The Company’s lead drug candidate Brilacidin is in a class of compounds called defensin-mimetics, small compounds that mimic the structure and function of defensins, also known as host defense peptides. The Company’s efforts are primarily focused on business development for the advancement of Brilacidin in the treatment of infectious diseases and Oral Mucositis. Ongoing activities include Brilacidin drug manufacturing, scientific report writing, and supportive research activities. The Company also owns an interest in BT BeaMedical Technologies Ltd. (“BTL”), formerly known as Squalus Medical Ltd., a private company developing a novel image guided surgical laser platform. Management is focused on other avenues of business development, including, but not limited to, joint ventures, mergers and acquisitions, strategic investments, and licensing agreements, for the purpose of diversifying corporate assets, although there can be no assurances that any agreement will be consummated in the future.
Company profile
Ticker
IPIX
Exchange
Website
CEO
Leo Ehrlich
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Cellceutix CORP, EconoShare, Inc.
SEC CIK
Corporate docs
Subsidiaries
IPIX Pharma Limited ...
IRS number
134303398
IPIX stock data
Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
1 Feb 24
8-K
Termination of a Material Definitive Agreement
5 Dec 23
10-Q
2024 Q1
Quarterly report
20 Nov 23
NT 10-Q
Notice of late quarterly filing
15 Nov 23
8-K
Changes in Registrant's Certifying Accountant
30 Oct 23
10-K
2023 FY
Annual report
28 Sep 23
10-Q
2023 Q3
Quarterly report
15 May 23
10-Q
2023 Q2
Quarterly report
15 Feb 23
NT 10-Q
Notice of late quarterly filing
15 Feb 23
8-K
Other Events
4 Jan 23
Latest ownership filings
4
LEO EHRLICH
4 Jan 23
4
Jane A. Harness
28 Sep 22
4
LEO EHRLICH
28 Sep 22
4
Zorik Spektor
28 Sep 22
4
Barry A Schechter
28 Sep 22
SC 13G/A
Kips Bay Select LP
5 Jul 22
SC 13G/A
Kips Bay Select LP
3 May 21
SC 13G
Kips Bay Select LP
11 Feb 21
SC 13G/A
Leviston Resources LLC
15 Jul 20
SC 13G
Leviston Resources LLC
10 Jul 20
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Jun 23 | Jun 22 | Jun 21 | Jun 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 864.00 k | 864.00 k | 864.00 k | 864.00 k | 864.00 k | 864.00 k |
Cash burn (monthly) | 218.00 k | 175.33 k | 288.67 k | 213.67 k | 225.67 k | 166.00 k |
Cash used (since last report) | 1.92 mm | 1.54 mm | 2.54 mm | 1.88 mm | 1.99 mm | 1.46 mm |
Cash remaining | -1.05 mm | -678.96 k | -1.68 mm | -1.02 mm | -1.12 mm | -596.82 k |
Runway (months of cash) | -4.8 | -3.9 | -5.8 | -4.8 | -5.0 | -3.6 |
Institutional ownership, Q1 2022
4.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 5.40 mm |
Total shares | 21.20 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Kips Bay Select | 21.20 mm | $5.40 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
30 Dec 22 | Ehrlich Leo | Class B Common Stock Class A Common Stock | Other | Dispose J | No | No | 0 | 11,307,527 | 0.00 | 4,333,936 |